|
1
|
di Clemente N, Jamin SP, Lugovskoy A,
Carmillo P, Ehrenfels C, Picard JY, Whitty A, Josso N, Pepinsky RB
and Cate RL: Processing of anti-mullerian hormone regulates
receptor activation by a mechanism distinct from TGF-beta. Mol
Endocrinol. 24:2193–2206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Josso N and Clemente N: Transduction
pathway of anti-Müllerian hormone, a sex-specific member of the
TGF-beta family. Trends Endocrinol Metab. 14:91–97. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Masiakos PT, MacLaughlin DT, Maheswaran S,
Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK,
Dombkowski DM, Ha TU, et al: Human ovarian cancer, cell lines, and
primary ascites cells express the human Mullerian inhibiting
substance (MIS) type II receptor, bind, and are responsive to MIS.
Clin Cancer Res. 5:3488–3499. 1999.PubMed/NCBI
|
|
4
|
Renaud EJ, MacLaughlin DT, Oliva E, Rueda
BR and Donahoe PK: Endometrial cancer is a receptor-mediated target
for Mullerian Inhibiting Substance. Proc Natl Acad Sci USA.
102:111–116. 2005. View Article : Google Scholar
|
|
5
|
Bakkum-Gamez JN, Aletti G, Lewis KA,
Keeney GL, Thomas BM, Navarro-Teulon I and Cliby WA: Müllerian
inhibiting substance type II receptor (MISIIR): A novel,
tissue-specific target expressed by gynecologic cancers. Gynecol
Oncol. 108:141–148. 2008. View Article : Google Scholar
|
|
6
|
Wei X, Dombkowski D, Meirelles K,
Pieretti-Vanmarcke R, Szotek PP, Chang HL, Preffer FI, Mueller PR,
Teixeira J, MacLaughlin DT, et al: Mullerian inhibiting substance
preferentially inhibits stem/progenitors in human ovarian cancer
cell lines compared with chemotherapeutics. Proc Natl Acad Sci USA.
107:18874–18879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anttonen M, Färkkilä A, Tauriala H,
Kauppinen M, Maclaughlin DT, Unkila-Kallio L, Bützow R and
Heikinheimo M: Anti-Müllerian hormone inhibits growth of AMH type
II receptor-positive human ovarian granulosa cell tumor cells by
activating apoptosis. Lab Invest. 91:1605–1614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meirelles K, Benedict LA, Dombkowski D,
Pepin D, Preffer FI, Teixeira J, Tanwar PS, Young RH, MacLaughlin
DT, Donahoe PK, et al: Human ovarian cancer stem/progenitor cells
are stimulated by doxorubicin but inhibited by Mullerian inhibiting
substance. Proc Natl Acad Sci USA. 109:2358–2363. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pépin D, Sosulski A, Zhang L, Wang D,
Vathipadiekal V, Hendren K, Coletti CM, Yu A, Castro CM, Birrer MJ,
et al: AAV9 delivering a modified human Mullerian inhibiting
substance as a gene therapy in patient-derived xenografts of
ovarian cancer. Proc Natl Acad Sci USA. 112:E4418–E4427. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim JH, MacLaughlin DT and Donahoe PK:
Müllerian inhibiting substance/anti-Müllerian hormone: A novel
treatment for gynecologic tumors. Obstet Gynecol Sci. 57:343–357.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Salhi I, Cambon-Roques S, Lamarre I, Laune
D, Molina F, Pugnière M, Pourquier D, Gutowski M, Picard JY, Xavier
F, et al: The anti-Müllerian hormone type II receptor: Insights
into the binding domains recognized by a monoclonal antibody and
the natural ligand. Biochem J. 379:785–793. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan QA, Simmons HH, Robinson MK, Russeva
M, Marasco WA and Adams GP: Development of engineered antibodies
specific for the Müllerian inhibiting substance type II receptor: A
promising candidate for targeted therapy of ovarian cancer. Mol
Cancer Ther. 5:2096–2105. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan QA, Robinson MK, Simmons HH, Russeva
M and Adams GP: Isolation of anti-MISIIR scFv molecules from a
phage display library by cell sorter biopanning. Cancer Immunol
Immunother. 57:367–378. 2008. View Article : Google Scholar
|
|
14
|
Bougherara H, Némati F, Nicolas A,
Massonnet G, Pugnière M, Ngô C, Le Frère-Belda MA, Leary A,
Alexandre J, Meseure D, et al: The humanized anti-human AMHRII mAb
3C23K exerts an anti-tumor activity against human ovarian cancer
through tumor-associated macrophages. Oncotarget. 8:99950–99965.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Estupina P, Fontayne A, Barret J-M,
Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M,
Chauvin M, et al: The anti-tumor efficacy of 3C23K, a
glyco-engineered humanized anti-MISRII antibody, in an ovarian
cancer model is mainly mediated by engagement of immune effector
cells. Oncotarget. 8:37061–37079. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gill SE, Zhang Q, Keeney GL, Cliby WA and
Weroha SJ: Investigation of factors affecting the efficacy of
3C23K, a human monoclonal antibody targeting MISIIR. Oncotarget.
8:85214–85223. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kersual N, Garambois V, Chardès T, Pouget
JP, Salhi I, Bascoul-Mollevi C, Bibeau F, Busson M, Vié H,
Clémenceau B, et al: The human Müllerian inhibiting substance type
II receptor as immunotherapy target for ovarian cancer. Validation
using the mAb 12G4. MAbs. 6:1314–1326. 2014. View Article : Google Scholar
|
|
18
|
Belville C, Jamin SP, Picard JY, Josso N
and di Clemente N: Role of type I receptors for anti-Müllerian
hormone in the SMAT-1 Sertoli cell line. Oncogene. 24:4984–4992.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons
KM and Donahoe PK: Müllerian inhibiting substance signaling uses a
bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and
induces SMAD6 expression. Mol Endocrinol. 15:946–959.
2001.PubMed/NCBI
|
|
20
|
Josso N, Racine C, di Clemente N, Rey R
and Xavier F: The role of anti-Müllerian hormone in gonadal
development. Mol Cell Endocrinol. 145:3–7. 1998. View Article : Google Scholar
|
|
21
|
Orvis GD, Jamin SP, Kwan KM, Mishina Y,
Kaartinen VM, Huang S, Roberts AB, Umans L, Huylebroeck D, Zwijsen
A, et al: Functional redundancy of TGF-beta family type I receptors
and receptor-Smads in mediating anti-Mullerian hormone-induced
Mullerian duct regression in the mouse. Biol Reprod. 78:994–1001.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sèdes L, Leclerc A, Moindjie H, Cate RL,
Picard JY, di Clemente N and Jamin SP: Anti-Müllerian hormone
recruits BMPR-IA in immature granulosa cells. PLoS One.
8:e815512013. View Article : Google Scholar
|
|
23
|
Visser JA, Olaso R, Verhoef-Post M, Kramer
P, Themmen AP and Ingraham HA: The serine/threonine transmembrane
receptor ALK2 mediates Müllerian inhibiting substance signaling.
Mol Endocrinol. 15:936–945. 2001.PubMed/NCBI
|
|
24
|
Zhan Y, Fujino A, MacLaughlin DT,
Manganaro TF, Szotek PP, Arango NA, Teixeira J and Donahoe PK:
Müllerian inhibiting substance regulates its receptor/SMAD
signaling and causes mesenchymal transition of the coelomic
epithelial cells early in Müllerian duct regression. Development.
133:2359–2369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Basal E, Ayeni T, Zhang Q, Langstraat C,
Donahoe PK, Pepin D, Yin X, Leof E and Cliby W: Patterns of
Müllerian inhibiting substance type II and candidate type I
receptors in epithelial ovarian cancer. Curr Mol Med. 16:222–231.
2016. View Article : Google Scholar
|
|
26
|
Pépin D, Hoang M, Nicolaou F, Hendren K,
Benedict LA, Al-Moujahed A, Sosulski A, Marmalidou A, Vavvas D and
Donahoe PK: An albumin leader sequence coupled with a cleavage site
modification enhances the yield of recombinant C-terminal Mullerian
Inhibiting Substance. Technology (Singap). 1:63–71. 2013.
View Article : Google Scholar
|
|
27
|
Pépin D: Modified mullerian inhibiting
substance (mis) proteins and uses thereof for the treatment of
diseases. WO2014/164891. 2014
|
|
28
|
Wilson CA, di Clemente N, Ehrenfels C,
Pepinsky RB, Josso N, Vigier B and Cate RL: Mullerian inhibiting
substance requires its N-terminal domain for maintenance of
biological activity, a novel finding within the transforming growth
factor-beta superfamily. Mol Endocrinol. 7:247–257. 1993.PubMed/NCBI
|
|
29
|
Cate RL, Mattaliano RJ, Hession C, Tizard
R, Farber NM, Cheung A, Ninfa EG, Frey AZ, Gash DJ, Chow EP, et al:
Isolation of the bovine and human genes for Müllerian inhibiting
substance and expression of the human gene in animal cells. Cell.
45:685–698. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Philibert P, Stoessel A, Wang W, Sibler
AP, Bec N, Larroque C, Saven JG, Courtête J, Weiss E and Martineau
P: A focused antibody library for selecting scFvs expressed at high
levels in the cytoplasm. BMC Biotechnol. 7:812007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Robin G and Martineau P: Synthetic
customized scFv libraries. Methods Mol Biol. 907:109–122. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Golay J, Choblet S, Iwaszkiewicz J,
Cérutti P, Ozil A, Loisel S, Pugnière M, Ubiali G, Zoete V,
Michielin O, et al: Design and validation of a novel generic
platform for the production of tetravalent IgG1-like bispecific
antibodies. J Immunol. 196:3199–3211. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kadouche J, Mach JP, Michielin O, Zoete V,
Iwaszkiewicz J, Cerutti M, Choblet S and Golay J: Multispecific
Antibodies. Patent WO2013005194. Filed July 6, 2012; issued January
10, 2013.
|
|
34
|
Duke GM, Hoffman MA and Palmenberg AC:
Sequence and structural elements that contribute to efficient
encephalomyocarditis virus RNA translation. J Virol. 66:1602–1609.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Loisel S, André PA, Golay J, Buchegger F,
Kadouche J, Cérutti M, Bologna L, Kosinski M, Viertl D, Delaloye
AB, et al: Antitumour effects of single or combined monoclonal
antibodies directed against membrane antigens expressed by human B
cells leukaemia. Mol Cancer. 10:422011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chan-Penebre E, Armstrong K, Drew A,
Grassian AR, Feldman I, Knutson SK, Kuplast-Barr K, Roche M,
Campbell J, Ho P, et al: Selective killing of SMARCA2- and
SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic
type cells by inhibition of EZH2: In vitro and in vivo preclinical
models. Mol Cancer Ther. 16:850–860. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang H, Vollmer M, De Geyter M,
Litzistorf Y, Ladewig A, Dürrenberger M, Guggenheim R, Miny P,
Holzgreve W and De Geyter C: Characterization of an immortalized
human granulosa cell line (COV434). Mol Hum Reprod. 6:146–153.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nishi Y, Yanase T, Mu Y, Oba K, Ichino I,
Saito M, Nomura M, Mukasa C, Okabe T, Goto K, et al: Establishment
and characterization of a steroidogenic human granulosa-like tumor
cell line, KGN, that expresses functional follicle-stimulating
hormone receptor. Endocrinology. 142:437–445. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
O Donnell RL, McCormick A, Mukhopadhyay A,
Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufman A, Soohoo S,
Elattar A, et al: The use of ovarian cancer cells from patients
undergoing surgery to generate primary cultures capable of
undergoing functional analysis. PLoS One. 9:e906042014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chung YJ, Kim HJ, Park SH, Yoon JH, Kim
MR, Nam SW, MacLaughlin DT, Donahoe PK and Kim JH: Transcriptome
analysis reveals that Müllerian inhibiting substance regulates
signaling pathways that contribute to endometrial carcinogenesis.
Int J Oncol. 46:2039–2046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Beck TN, Korobeynikov VA, Kudinov AE,
Georgopoulos R, Solanki NR, Andrews-Hoke M, Kistner TM, Pépin D,
Donahoe PK, Nicolas E, et al: Anti-Müllerian hormone signaling
regulates epithelial plasticity and chemoresistance in lung cancer.
Cell Rep. 16:657–671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Köhler G, Howe SC and Milstein C: Fusion
between immunoglobulin-secreting and nonsecreting myeloma cell
lines. Eur J Immunol. 6:292–295. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang YE: Non-Smad signaling pathways of
the TGF-β family. Cold Spring Harb Perspect Biol. 9:92017.
View Article : Google Scholar
|
|
44
|
Horbelt D, Denkis A and Knaus P: A
portrait of transforming growth factor β superfamily signalling:
Background matters. Int J Biochem Cell Biol. 44:469–474. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mazumder S, Johnson JM, Swank V, Dvorina
N, Martelli E, Ko J and Tuohy VK: Primary immunoprevention of
epithelial ovarian carcinoma by vaccination against the
extracellular Domain of anti-Müllerian hormone receptor II. Cancer
Prev Res (Phila). 10:612–624. 2017. View Article : Google Scholar
|
|
46
|
Song JY, Chen KY, Kim SY, Kim MR, Ryu KS,
Cha JH, Kang CS, MacLaughlin DT and Kim JH: The expression of
Müllerian inhibiting substance/anti-Müllerian hormone type II
receptor protein and mRNA in benign, borderline and malignant
ovarian neoplasia. Int J Oncol. 34:1583–1591. 2009.PubMed/NCBI
|
|
47
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Brinkmann U and Kontermann RE: The making
of bispecific antibodies. MAbs. 9:182–212. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Carter PJ and Lazar GA: Next generation
antibody drugs: Pursuit of the 'high-hanging fruit'. Nat Rev Drug
Discov. 17:197–223. 2018. View Article : Google Scholar
|
|
50
|
Labrijn AF, Janmaat ML, Reichert JM and
Parren PW: Bispecific antibodies: A mechanistic review of the
pipeline. Nat Rev Drug Discov. 18:585–608. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kontermann RE: Dual targeting strategies
with bispecific antibodies. MAbs. 4:182–197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Spiess C, Zhai Q and Carter PJ:
Alternative molecular formats and therapeutic applications for
bispecific antibodies. Mol Immunol. 67:95–106. 2015. View Article : Google Scholar : PubMed/NCBI
|
